HOME >> BIOLOGY >> NEWS
Gene silencing directs muscle-derived stem cells to become bone-forming cells

BALTIMORE - Using a relatively new technology called RNA interference to turn off genes that regulate cell differentiation, University of Pittsburgh researchers have demonstrated they can increase the propensity of muscle-derived stem cells (MDSCs) to become bone-forming cells. Based on these results, the investigators believe that by turning off specific genetic factors they can control the capacity of MDSCs as a means of treating various musculoskeletal diseases and injuries.

RNA interference is a simple yet powerful technique that uses short interfering RNAs (siRNAs) small molecules that prevent a gene from being expressed to turn off the production of specific proteins in a cell. In their study, the Pitt researchers generated siRNAs to two mouse genes: MyoD1, a master gene that regulates the formation of muscle cells or fibers (myogenesis), and Smad6, which encodes a molecule that specifically inhibits a cell's ability to respond to bone-forming, or osteogenic, signals.

When the researchers examined cultured cells in which myogenesis was inhibited, they found a significant increase in the cells' bone-forming potential. However, contrary to their expectations, the researchers did not observe any bone formation when the cells were implanted in skeletal muscle. Yet, when they turned off ostegenic inhibition in these same cells using Smad6 siRNA prior to implanting them in mice, 60 percent of the mice developed radiologically detectable bone within three weeks.

"By understanding the genetic mechanisms that regulate a cell's propensity to differentiate into one type of cell line over another, we may be able to regulate their ability to generate bone for the treatment of various diseases and injuries of the musculoskeletal system, such as osteoporosis or severe fractures," said first author Jonathan B. Pollett, Ph.D., research associate, department of orthopaedic surgery, Children's Hospital of Pittsburgh. Corresponding author Johnny Huard,
'"/>


1-Jun-2006


Page: 1 2

Related biology news :

1. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
2. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
3. Pathway toward gene silencing described in plants
4. miRNA-mediated silencing of mRNAs
5. New mechanism for essential genome-wide gene silencing identified
6. Proteins role in hemoglobin gene silencing identified
7. Prediction of a prokaryotic RNA-silencing system
8. Twin molecular scissors link creation of microRNAs with gene-silencing
9. Gene silencing technique offers new strategy for treating, curing disease
10. Molecular steps involved in the creation of gene-silencing microRNAs identified
11. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused ... Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine ... and is expected to deliver therapeutic levels of olanzapine for a period of 3 ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
Cached News: